Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 2 3Phase 1 3

Status

Completed 3

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × tepotinib × Clear all
NCT03492437 2023-08-07

Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran Etexilate

Merck KGaA, Darmstadt, Germany

Phase 1 Completed
20 enrolled 14 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03531762 2023-07-28

Effect of a Proton Pump Inhibitor on the PK of Tepotinib

Merck KGaA, Darmstadt, Germany

Phase 1 Completed
12 enrolled 16 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01014936 2022-08-24

First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors

EMD Serono

Phase 1 Completed
149 enrolled 41 charts
Other solid neoplasm

Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available

Data powered by HemOnc (CC BY 4.0) Colophon âš¡